AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo

FEBS Journal

Volumn 280, Issue 21, 2013, Pages 5307-5316

  Devlin, Jennifer R ^a   Hannan, Katherine M ^a   Ng, Pui Y ^a   Bywater, Megan J ^a   Shortt, Jake ^a   Cullinane, Carleen ^a   McArthur, Grant A ^a,b   Johnstone, Ricky W ^a,b   Hannan, Ross D ^a,b,c,d   Pearson, Richard B ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

AKT; lymphoma; MYC; oncogenesis; ribosome biogenesis

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; MYC PROTEIN; PROTEIN KINASE B; RIBOSOME DNA; RIBOSOME RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AXILLARY LYMPH NODE; B CELL LYMPHOMA; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CIRCULATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA TRANSCRIPTION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOLOGY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SIGNAL TRANSDUCTION;

AKT; LYMPHOMA; MYC; ONCOGENESIS; RIBOSOME BIOGENESIS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DROMAIIDAE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, RIBOSOMAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

MUS;

EID: 84886095337     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12135     Document Type: Conference Paper

References (43)

1. Altomare DA, &, Testa JR, (2005) Perturbations of the AKT signalling pathway in human cancer. Oncogene 24, 7455-7464.
2. Shaw RJ, &, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumor cell growth. Nature 441, 424-430.
3. Jiang BH, &, Liu LZ, (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102, 19-65.
4. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, &, Lowe SW, (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337.
5. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, et al,. (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108, 4178-4186.
6. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, &, Phillips WA, (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 7678-7681.
7. Campbell IG, Russell SE, &, Phillips WA, (2005) PIK3CA mutations in ovarian cancer. Clin Cancer Res 11, 7042-7043.
8. Solomon B, &, Pearson RB, (2009) Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol 4, 787-791.
9. Hannan KM, Sanij E, Hein N, Hannan RD, &, Pearson RB, (2011) Signaling to the ribosome in cancer-it is more than just mTORC1. IUBMB Life 63, 79-85.
10. Ruggero D, &, Pandolfi PP, (2003) Does the ribosome translate cancer? Nat Rev Cancer 3, 179-192.
11. Chan JC, Hannan KM, Riddell K, Ng PY, Peck A, Lee RS, Hung S, Astle MV, Bywater M, Wall M, et al,. (2011) AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal 4, ra56.
12. Poortinga G, Hannan KM, Snelling H, Walkley CR, Jenkins A, Sharkey K, Wall M, Brandenburger Y, Palatsides M, Pearson RB, et al,. (2004) MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J 23, 3325-3335.
13. dori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, &, White RJ, (2005) c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7, 311-318.
14. Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D, Holloway TP, Hannan RD, &, McArthur GA, (2011) c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res 39, 3267-3281.
15. Gomez-Roman N, Grandori C, Eisenman RN, &, White RJ, (2003) Direct activation of RNA polymerase III transcription by c-MYC. Nature 421, 290-294.
16. Moss T, Langlois F, Gagnon-Kugler T, &, Stefanovsky V, (2007) A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis. Cell Mol Life Sci 64, 29-49.
17. Grummt I, (2003) Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev 17, 1691-1702.
18. Ruggero D, (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69, 8839-8843.
19. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH, &, Ruggero D, (2008) Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456, 971-975.
20. Hsieh AC, Truitt ML, &, Ruggero D, (2011) Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 105, 329-336.
21. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al,. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61.
22. Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, et al,. (2012) Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51-65.
23. Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, Bywater MJ, Kinross KM, Astle MV, Waldeck K, et al,. (2013) The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov 3, 82-95.
24. Sheppard KE, Kinross KM, Solomon B, Pearson RB, &, Phillips WA, (2012) Targeting PI3K/AKT/mTOR signaling in cancer. Crit Rev Oncog 17, 69-95.
25. Yan L, (2009) MK-2206: a potent oral allosteric AKT inhibitor. Presented at the AACR Annual Meeting, April 19 2009 abstract number DDT01-1, http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey= {F42C4FE4-1DC4-4996-9EED-AAC71D2D235E}&SKey={B8684E46-582B-4893-A4AA- 1D24A0DFF3B9}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey= {728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}.
26. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al,. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9, 1956-1967.
27. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, et al,. (2012) Biomarkers of response to AKT inhibitor MK-2206 in breast cancer. Clin Cancer Res 18, 5816-5828.
28. Li Z, Attayan N, Ramalingam S, &, Thiele CJ, (2012) Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin Cancer Res 18, 3603-3615.
29. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, &, Adams JM, (1988) The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukaemia of early B cells. J Exp Med 167, 353-371.
30. Hoffman B, &, Liebermann DA, (2008) Apoptotic signalling by c-MYC. Oncogene 27, 6462-6472.
31. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, &, Roussel MF, (1998) Myc signalling via the ARF tumor suppressor regulates p53 dependent apoptosis and immortalisation. Genes Dev 12, 2424-2433.
32. Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, et al,. (2011) Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 71, 1418-1430.
33. Hannan KM, Sanij E, Rothblum L, Pearson RB, &, Hannan RD, (2012) Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta, doi:pii:S1874-9399(12)00185-X. 10.1016/j.bbagrm.2012.10.014.
34. s6k. EMBO J 16, 3693-3704.
35. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, &, Sawyers CL, (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493.
36. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, et al,. (2012) mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 4, ra84.
37. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, et al,. (2012) Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2, 56-67.
38. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al,. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338.
39. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al,. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507-2516.
40. Mayo LD, &, Donner DB, (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98, 11598-11603.
41. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, &, Greenberg ME, (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
42. Datta SR, Brunet A, &, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13, 2905-2927.
43. Matheny RW Jr, &, Adamo ML, (2009) Current perspectives on Akt Akt-ivation and Akt-ions. Exp Biol Med 234, 1264-1270.